Intravenous siRNA of Brain Cancer with Receptor Targeting and Avidin–Biotin Technology
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The effective delivery of short interfering RNA (siRNA) to brain following intravenous administration requires the development of a delivery system for transport of the siRNA across the brain capillary endothelial wall, which forms the blood–brain barrier in vivo.
siRNA was delivered to brain in vivo with the combined use of a receptor-specific monoclonal antibody delivery system, and avidin–biotin technology. The siRNA was mono-biotinylated on either terminus of the sense strand, in parallel with the production of a conjugate of the targeting MAb and streptavidin.
Rat glial cells (C6 or RG-2) were permanently transfected with the luciferase gene, and implanted in the brain of adult rats. Following the formation of intra-cranial tumors, the rats were treated with a single intravenous injection of 270 μg/kg of biotinylated siRNA attached to a transferrin receptor antibody via a biotin–streptavidin linker. The intravenous administration of the siRNA caused a 69–81% decrease in luciferase gene expression in the intracranial brain cancer in vivo.
Brain delivery of siRNA following intravenous administration is possible with siRNAs that are targeted to brain with the combined use of receptor specific antibody delivery systems and avidin–biotin technology.
- M. T. McManus, P. A. Sharp. Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. 3:737–747 (2002). CrossRef
- P. J. Paddison, A. A. Caudy, E. Bernstein, G. J. Hannon, D. S. Conklin. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16:948–958 (2002). CrossRef
- S. Spagnou, A. D. Miller, M. Keller. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43:13348–13356 (2004). CrossRef
- A. Jahraus, T. E. Tjelle, T. Berg, A. Habermann, B. Storrie, O. Ullrich, et al. In vitro fusion of phagosomes with different endocytic organelles from J774 macrophages. J. Biol. Chem. 273:30379–30390 (1998). CrossRef
- W. M. Pardridge. shRNA and siRNA delivery to the brain. Adv. Drug Deliv. Rev. 59:141–152 (2007). CrossRef
- Y. Zhang, Y. F. Zhang, J. Bryant, A. Charles, R. J. Boado, W. M. Pardridge. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10:3667–3677 (2004). CrossRef
- N. M. Green. Avidin and streptavidin. Methods Enzymol. 184:51–67 (1990).
- T. Suzuki, D. Wu, F. Schlachetzki, J. Y. Li, R. J. Boado, W. M. Pardridge. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J. Nucl. Med. 45:1766–1775 (2004).
- W. M. Pardridge, Y. S. Kang, J. L. Buciak, J. Yang. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood–brain barrier in vivo in the primate. Pharm. Res. 12:807–816 (1995). CrossRef
- W. M. Pardridge, J. L. Buciak, P. M. Friden. Selective transport of an anti-transferrin receptor antibody through the blood–brain barrier in vivo. J. Pharmacol. Exp. Ther. 259:66–70 (1991).
- H. J. Lee, B. Engelhardt, J. Lesley, U. Bickel, W. M. Pardridge. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood–brain barrier in mouse. J. Pharmacol. Exp. Ther. 292:1048–1052 (2000).
- W. M. Pardridge, R. J. Boado, Y. S. Kang. Vector-mediated delivery of a polyamide (“peptide”) nucleic acid analogue through the blood–brain barrier in vivo. Proc. Natl. Acad. Sci. U.S.A. 92:5592–5596 (1995). CrossRef
- D. Wu, J. Yang, W. M. Pardridge. Drug targeting of a peptide radiopharmaceutical through the primate blood–brain barrier In vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest. 100:1804–1812 (1997). CrossRef
- R. J. Boado, W. M. Pardridge. Ten nucleotide cis element in the 3-untranslated region of the GLUT1 glucose transporter mRNA increases gene expression via mRNA stabilization. Brain Res. Mol. Brain Res. 59:109–113 (1998). CrossRef
- Y. Zhang, R. J. Boado, W. M. Pardridge. In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J. Gene Med. 5:1039–1045 (2003). CrossRef
- S. M. Elbashir, J. Harborth, K. Weber, T. Tuschl. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26:199–213 (2002). CrossRef
- R. F. Barth. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J. Neurooncol. 36:91–102 (1998). CrossRef
- Y. L. Chiu, T. M. Rana. RNAi in human cells: basic structural and functional features of small interfering RNA. Mol. Cell 10:549–561 (2002). CrossRef
- A. de Fougerolles, M. Manoharan, R. Meyers, H. P. Vornlocher. RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics. Methods Enzymol. 392:278–296 (2005).
- I. Pilz, E. Schwarz, W. Durchschein, A. Licht, M. Sela. Effect of cleaving interchain disulfide bridges on the radius of gyration and maximum length of anti-poly(d-alanyl) antibodies before and after reaction with tetraalanine hapten. Proc. Natl. Acad. Sci. USA. 77:117–121 (1980). CrossRef
- M. Grzelinski, B. Urban-Klein, T. Martens, K. Lamszus, U. Bakowsky, S. Hobel, F. Czubayko, A. Aigner. RNA interference-mediated gene silencing of pleiotrophin though polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 17:751–766 (2006). CrossRef
- Y. K. Song, F. Liu, S. Chu, D. Liu. Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration. Hum. Gene Ther. 8:1585–1594 (1997).
- K. Miyawaki-Shimizu, D. Predescu, J. Shimizu, M. Broman, S. Predescu, A. B. Malik. siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathwayAm. J. Physiol. Lung. Cell. Mol. Physiol. 290:L405–L413 (2006). CrossRef
- P. Kumar, H. Wu, J. L. McBride, K.-E. Jung, M. H. Kim, B. L. Davidson, S. K. Lee, P. Shankar, N. Manjunath. Transvascular delivery of small interfering RNA to the central nervous systemNature. 448:39–43 (2007). CrossRef
- B. T. Hawkins, R. D. Egleton, T. P. Davis. Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. Am. J. Physiol. Heart Circ. Physiol. 289:H212–H219 (2005). CrossRef
- H. J. Lee, Y. Zhang, C. Zhu, K. Duff, W. M. Pardridge. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J. Cereb. Blood Flow Metab. 22:223–231 (2002). CrossRef
- S. M. Elbashir, J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, T. Tuschl. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498 (2001). CrossRef
- M. Egli, G. Minasov, V. Tereshko, P. S. Pallan, M. Teplova, G. B. Inamati, E. A. Lesnik, S. R. Owens, B. S. Ross, T. P. Prakash, M. Manoharan. Probing the influence of stereoelectronic effects on the biophysical properties of oligonucleotides: comprehensive analysis of the RNA affinity, nuclease resistance, and crystal structure of ten 2-O-ribonucleic acid modifications. Biochemistry 44:9045–9057 (2005). CrossRef
- T. Yoshikawa, W. M. Pardridge. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptorJ. Pharmacol. Exp. Ther. 263:897–903 (1994).
- M. L. Penichet, Y. S. Kang, W. M. Pardridge, S. L. Morrison, S.U. Shin. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. J. Immunol. 163:4421–4426 (1999).
- Intravenous siRNA of Brain Cancer with Receptor Targeting and Avidin–Biotin Technology
Volume 24, Issue 12 , pp 2309-2316
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- blood–brain barrier
- monoclonal antibody
- RNA interference
- Industry Sectors